These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 9698691)

  • 21. Why does androgen deprivation enhance the results of radiation therapy?
    Wo JY; Zietman AL
    Urol Oncol; 2008; 26(5):522-9. PubMed ID: 18774467
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Randomized comparative study of 3 versus 8-month neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects.
    Gleave ME; Goldenberg SL; Chin JL; Warner J; Saad F; Klotz LH; Jewett M; Kassabian V; Chetner M; Dupont C; Van Rensselaer S;
    J Urol; 2001 Aug; 166(2):500-6; discussion 506-7. PubMed ID: 11458055
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment of prostate cancer with regional lymph node (N1) metastasis.
    Pollack A; Horwitz EM; Movsas B
    Semin Radiat Oncol; 2003 Apr; 13(2):121-9. PubMed ID: 12728441
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Additional surgical intervention after radical prostatectomy, radiation therapy, androgen-deprivation therapy, or watchful waiting.
    Berge V; Thompson T; Blackman D
    Eur Urol; 2007 Oct; 52(4):1036-43. PubMed ID: 17178188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumour volume is an independent predictor of prostate-specific antigen recurrence in patients undergoing radical prostatectomy for clinically localized prostate cancer.
    Nelson BA; Shappell SB; Chang SS; Wells N; Farnham SB; Smith JA; Cookson MS
    BJU Int; 2006 Jun; 97(6):1169-72. PubMed ID: 16686706
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Persistent expression of Aurora-A after neoadjuvant hormonal therapy as a predictor of a poor clinical outcome in patients undergoing radical prostatectomy for prostate cancer.
    Furukawa J; Miyake H; Takenaka A; Hara I; Fujisawa M
    BJU Int; 2007 Aug; 100(2):310-4. PubMed ID: 17511772
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prostate cancer-specific survival in men treated with hormonal therapy after failure of radical prostatectomy.
    Porter CR; Gallina A; Kodama K; Gibbons RP; Correa R; Perrotte P; Karakiewicz PI
    Eur Urol; 2007 Aug; 52(2):446-52. PubMed ID: 17140724
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [What is safe in the therapy of advanced prostatic cancer?].
    Gropp C; Burk K
    Internist (Berl); 1985 Dec; 26(12):765-70. PubMed ID: 3936819
    [No Abstract]   [Full Text] [Related]  

  • 29. Prostatic cancer--what to do? Staging and prognostic factors in the primary therapy decision.
    Faul P
    Eur Urol; 1992; 22(2):89-98. PubMed ID: 1478236
    [No Abstract]   [Full Text] [Related]  

  • 30. A randomized trial comparing radical prostatectomy plus endocrine therapy versus external beam radiotherapy plus endocrine therapy for locally advanced prostate cancer: results at median follow-up of 102 months.
    Akakura K; Suzuki H; Ichikawa T; Fujimoto H; Maeda O; Usami M; Hirano D; Takimoto Y; Kamoto T; Ogawa O; Sumiyoshi Y; Shimazaki J; Kakizoe T;
    Jpn J Clin Oncol; 2006 Dec; 36(12):789-93. PubMed ID: 17082219
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Histopathologic changes due to combination of androgen deprivation and transurethral microwave thermotherapy in patients with localized prostate cancer].
    Suzuki R; Jujo Y; Koshiba K; Hoshiai O; Endo T; Aihara M; Nakajo H; Ohori M
    Hinyokika Kiyo; 2009 Feb; 55(2):79-85. PubMed ID: 19301612
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Limited value of perineural invasion in radical prostatectomy specimens as a predictor of biochemical recurrence in Japanese men with clinically localized prostate cancer.
    Miyake H; Sakai I; Harada K; Eto H; Hara I
    Hinyokika Kiyo; 2005 Apr; 51(4):241-6. PubMed ID: 15912782
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Overexpression of the cyclin-dependent kinase inhibitor p16 is associated with tumor recurrence in human prostate cancer.
    Lee CT; Capodieci P; Osman I; Fazzari M; Ferrara J; Scher HI; Cordon-Cardo C
    Clin Cancer Res; 1999 May; 5(5):977-83. PubMed ID: 10353729
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy.
    Paparel P; Cronin AM; Savage C; Scardino PT; Eastham JA
    Eur Urol; 2009 Feb; 55(2):404-10. PubMed ID: 18639970
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Hormone therapy of locally advanced and metastatic prostate carcinoma].
    Rübben H
    Praxis (Bern 1994); 2001 Sep; 90(38):1641-4. PubMed ID: 11675917
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Study of intermittent endocrine therapy in patients presenting with biologic recurrence after radical prostatectomy or radiotherapy].
    de la Taille A; Zerbib M; Conquy S; Amsellem-Ouazana D; Saighi D; Debré B
    Prog Urol; 2002 Apr; 12(2):240-7. PubMed ID: 12108338
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cancer-specific mortality after radiation therapy with short-course hormonal therapy or radical prostatectomy in men with localized, intermediate-risk to high-risk prostate cancer.
    Tsai HK; Chen MH; McLeod DG; Carroll PR; Richie JP; D'Amico AV
    Cancer; 2006 Dec; 107(11):2597-603. PubMed ID: 17039498
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
    Carver BS; Bianco FJ; Scardino PT; Eastham JA
    J Urol; 2006 Aug; 176(2):564-8. PubMed ID: 16813890
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Correlation between re-biopsy one year after endocrine therapy and long-term prognosis in localized prostate cancer].
    Kameoka H; Katayose K; Kumakawa K; Shiraiwa Y; Uchida H; Takahashi Y; Yazaki J; Yamaguchi O
    Gan To Kagaku Ryoho; 2005 Jan; 32(1):57-63. PubMed ID: 15675583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
    D'Amico A
    BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.